Skip to main content

Advertisement

Table 1 Characteristics of the patients and changes of their weight during the study. Both individual and mean weight changes are presented. p-values are based on paired samples tests for the patients who have completed the corresponding follow-up interval. The dose of topiramate is the highest dose reached. Under "Concomitant medication" the drugs that are undelined were exchanged with topiramate.

From: Add-on topiramate reduces weight in overweight patients with affective disorders: a clinical case series

Patient N Gender Age DSM-IV Concomitant medication Topiramate dose (mg) Start Weight change from start (months)
       BMI (kg/m2) weight (kg) 3 months 6 months 9 months 12 months
1 f 49 UD Nortryptiline, carbamazepine 600 42.4 110 -8 -10 -11 -12.5
2 f 48 BPI Risperidone, lamotrigine, lofepramine 400 37.2 87 -9.5 -14 -12 -8
3 f 49 BPI Quetiapine, mirtazapine, lithium, venlafaxine 200 42.3 99 -1 -5 -11 -14
4 m 50 BPII Lithium, paroxetine 300 47.7 146 -10.5 -21 -26 -12.5
5 f 28 BPI Lithium 200 31.5 79 -6 -10.5   
6 m 31 BPII Lithium, reboxetine, trazodone, valproate 300 40.5 120 -6 -7.5 -6.5 -8
7 m 40 BPI Olanzapine, fluoxetine 400 30.3 102.5 -1 +5 -1.5 -5.5
8 f 41 BPII Fluphenazine, carbamazepine, paroxetine 250 34.7 90 -7 -14 -18 -22.5
9 f 70 UD Mirtazapine, lithium, amisulpride, venlafaxine 200 44.4 116.5 -3 -4 -4 -4
10 f 54 BPII Lithium, clomipramine, flupenthixol, trazodone 250 34.7 80 -1.5 -2.5 -2 +0.5
11 f 48 UD Phenelzine, amisulpride, valproate 250 31.0 88.5 -3.5 -8.5   
12 m 33 BPI Lithium, carbamazepine 200 38.7 134 -2.5 -1   
Mean reduction (kg) 4.96 7.75 10.2 9.61
SD 3.33 6.9 7.98 6.69
p-value 0.001 0.003 0.005 0.003